Preclinical RA: Can We Prevent Arthritis?

Background. Anti-CCP antibodies and rheumatoid factor can appear years before clinical arthritis, often accompanied by arthralgia and subclinical inflammation on imaging. This creates a window in which treatment might prevent the disease rather than control it.

What the studies showed. PRAIRI tested a single dose of rituximab in people with arthralgia and positive ACPA and RF. It did not prevent RA but delayed onset by about a year, suggesting B cells are active early. TREAT EARLIER enrolled people with arthralgia and MRI-detected inflammation and gave a single glucocorticoid injection followed by a year of methotrexate. It did not reduce progression to RA, but it improved pain, function and MRI inflammation, and those benefits persisted. APIPPRA treated ACPA-positive people with arthralgia using 12 months of abatacept, which blocks T-cell costimulation. Fewer participants progressed to arthritis during treatment, but some of the benefit faded after abatacept stopped. The ARIAA trial of abatacept, in people with ACPA and MRI inflammation, reported a similar direction of effect.

How it changes practice. No drug is approved to prevent RA, and these results do not yet support routine treatment of seropositive arthralgia outside trials. They do support referring at-risk patients early, monitoring closely and addressing modifiable risks such as smoking, periodontal disease and obesity. For patients who ask, prevention trials are a real option, and ClinicalTrials.gov lists active studies.

Open questions. Who is at highest risk, and can we identify them using antibody titers, imaging and symptoms? Is delay meaningful if disease eventually develops? How long should treatment continue, and do different mechanisms fit different stages of preclinical disease? Cost, safety and the risk of overtreating people who would never develop RA all remain central concerns.